Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7760184 | 0.86 | ALDH1A1 (0.56) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL6702870 | 0.86 | MMP1 (0.54) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL30429390 | 0.86 | ALDH1A1 (0.56) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL10800307 | 0.84 | ALDH1A1 (0.56) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL31554190 | 0.84 | MAPT (0.57) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL6176778 | 0.84 | ALDH1A1 (0.55) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL114463 | 0.84 | PARP10 (0.57) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL777869 | 0.84 | MAPT (0.57) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL11343363 | 0.84 | MAPT (0.45) | MAPTKMT2ARAB9APOLBPKM | |
| SCHEMBL9064611 | 0.82 | HCAR2 (0.51) | MAPTKMT2ARAB9APOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889901-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | ABBOTT LAB (US) | 2001-09-19 | — | — | EP | claimed |
| EP-0914334-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | ABBOTT LAB (US) | 2001-05-30 | — | — | EP | claimed |
| EP-0914334-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | Abbott Laboratories (US) | 1999-05-12 | — | — | EP | claimed |
| EP-0889901-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | Abbott Laboratories (US) | 1999-01-13 | — | — | EP | claimed |
| US-5710247-A | DEPROTECTING OLIGOPEPTIDE; COUPLING | ABBOTT LABORATORIES (US) | 1998-01-20 | — | — | US | claimed |
| US-5710246-A | COUPLING OLIGOPEPTIDES; DEPROTECTING | ABBOTT LABORATORIES (US) | 1998-01-20 | — | — | US | claimed |
| WO-1997034923-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-09-25 | — | — | WO | claimed |
| WO-1997034924-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-09-25 | — | — | WO | claimed |
| CN-118591551-A | Synthetic methods for producing modified GCC receptor agonists | 硬木药品公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-102958914-B | 1-phenyl substituted heterocyclic derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| CN-1324006-C | Beta-amino acid nitrile derivs. | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| CN-1436168-A | Beta-amino acid nitrile derivs. | HOFFMANN LA ROCHE (CH) | 2003-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | MAPT 4762/4885KMT2A 4417/4885RAB9A 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.